Biology and novel therapy of AML expressing somatic or germline mutant RUNX1
表达体细胞或种系突变体 RUNX1 的 AML 的生物学和新疗法
基本信息
- 批准号:10308449
- 负责人:
- 金额:$ 48.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-01 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:AgeApoptosisBCL2 geneBackBindingBiologyBromodomainC-terminalCRISPR screenCell LineCell modelCellsChromatinComplexCore-Binding FactorCoupledDNA BindingDNA Polymerase IIDependenceDysmyelopoietic SyndromesEnhancersExhibitsExonsFamilial Platelet DisorderGenesGenetic TranscriptionGerm LinesGerm-Line MutationGrowthHematopoiesisHematopoietic stem cellsHomologous TransplantationIn VitroIntronsLengthLibrariesMalignant - descriptorMediatingMessenger RNAMusMutationMyeloproliferative diseaseNetwork-basedOncogenesOutcomePatient riskPatientsPrognosisProtacProtein IsoformsProteinsRNARUNX1 geneReaderRecurrent diseaseRepressionResidual stateResistanceSomatic MutationTimeTranscriptional Activation Domainantagonistbasechemotherapychromatin proteinepigenomegraft vs host diseasehomoharringtonineimprovedin vivoinhibitorknock-downloss of function mutationmutantnew therapeutic targetnovelnovel therapeuticspatient derived xenograft modelpre-clinicalpreclinical efficacyrecruitsmall hairpin RNAstem cellstargeted treatmenttranscription factortranscriptome
项目摘要
Project Summary:
RUNX1 is the DNA-binding subunit of the core binding factor (CBF) complex and a master-regulator
transcription factor, which is involved in normal and malignant hematopoiesis. Somatic, heterozygous RUNX1
mutations commonly occur in Myelodysplastic Syndrome (MDS) (10%), as well as in secondary (s) or de novo
AML (~10%). Germline mutations in RUNX1 cause the highly penetrant (~40%) autosomal dominant, Familial
Platelet Disorder (FPD), which can evolve into myeloid malignancy (FPD-MM). Majority of mutant (mt) RUNX1
behave mostly as loss of function mutations, conferring relative therapy-resistance and poorer survival in
patients with AML. Consequently, there is a strong unmet need to develop novel therapies for AML expressing
somatic or germline mtRUNX1. Our preliminary studies have demonstrated for the first time that shRNA-
mediated knockdown of RUNX1 (mutant and wild-type) or disruption of its binding to CBFβ induces greater
lethality in AML progenitor cells (HPCs) expressing mtRUNX1 compared to wild-type (wt) RUNX1. We also
found that the +24kb enhancer (eR1) within the intragenic super-enhancer (SE) of RUNX1 regulates its
transcription in AML cells. The chromatin reader BET (Bromodomain Extra-terminal) protein (BETP) BRD4
promotes transcription of RUNX1 and its targets. BRD4 degradation or eviction from chromatin, or gene-editing
of the +24kb RUNX1 eR1, induces lethality in AML cells. By determining and utilizing the mRNA signature from
RUNX1-depleted (by shRNA) AML cells, we queried, through LINCS1000-CMap (Connectivity Mapping)
analysis, for expression mimickers (EMs). We identified novel EMs that repress RUNX1 and its targets and
induce significantly more apoptosis of AML cells expressing mtRUNX1 versus wtRUNX1. Therefore, the
hypothesis motivating our studies is that knocking down of levels of RUNX1 and its targets will induce lethality
not only in AML blasts expressing somatic mtRUNX1 but also in FPD/MM HPCs expressing germline
mtRUNX1. The specific aims of studies proposed are: AIM 1: To determine impact on active enhancers,
transcriptome and pre-clinical in vitro and in vivo efficacy of BETP antagonist along with its co-repression of
RUNX1, BCL2 and CDK6, alone or in combination with BCL2 or CDK6 inhibitor, in AML blasts and patient-
derived xenograft (PDX) models expressing somatic mutant RUNX1. Additionally, we will evaluate pre-clinical
efficacy of co-targeting CRISPR-Cas9 screen-discovered top ‘druggable’ dependencies along with BETP
antagonist against AML blasts expressing somatic mtRUNX1. AIM 2: To elucidate pre-clinical in vitro and in
vivo efficacy of the EMs homoharringtonine (omacetaxine) or fedratinib alone and in combination with BETP
antagonists against patient-derived AML blasts and PDX models expressing somatic mtRUNX1. AIM 3: To
determine pre-clinical in vitro and in vivo efficacy of selected EMs that repress RUNX1 and its targets against
patient-derived HPCs from FPD-MM expressing germline mtRUNX1 and other somatic co-mutations versus
HPCs from RUNX1-FPD expressing only germline mtRUNX1.
项目摘要:
RUNX 1是核心结合因子(CBF)复合物的DNA结合亚基,也是一个主调节因子
转录因子,其参与正常和恶性造血。体细胞杂合RUNX 1
突变通常发生在骨髓增生异常综合征(MDS)(10%),以及继发性或新发
AML(~10%)。RUNX 1的生殖系突变导致高度外显(~40%)的常染色体显性遗传,家族性
血小板疾病(FPD),可演变为骨髓恶性肿瘤(FPD-MM)。大多数突变体(mt)RUNX 1
主要表现为功能突变的丧失,赋予相对的治疗抗性和较差的生存率,
AML患者。因此,对于开发用于表达AML的新疗法存在强烈的未满足的需求。
体细胞或生殖系mtRUNX 1。我们的初步研究首次证明了shRNA-
介导的RUNX 1(突变体和野生型)敲低或其与CBFβ结合的破坏诱导了更大的
与野生型(wt)RUNX 1相比,表达mtRUNX 1的AML祖细胞(HPC)的致死率。我们也
发现RUNX 1基因内超级增强子(SE)中的+24kb增强子(eR 1)调节其
在AML细胞中的转录。染色质阅读器BET(Bromodomain Extra-terminal)蛋白(BETP)BRD 4
促进RUNX 1及其靶点的转录。BRD 4降解或从染色质中驱逐,或基因编辑
+24kb RUNX 1 eR 1的表达在AML细胞中诱导致死性。通过确定和利用mRNA签名,
我们通过LINCS 1000-CMap(Connectivity Mapping)查询了RUNX 1缺失(通过shRNA)的AML细胞
分析,用于表达模拟物(EM)。我们鉴定了抑制RUNX 1及其靶点的新型EM,
诱导表达mtRUNX 1的AML细胞比表达wtRUNX 1的AML细胞显著更多的凋亡。因此
激发我们研究的假设是RUNX 1及其靶点的水平敲低将诱导致死性
不仅在表达体细胞mtRUNX 1的AML母细胞中,而且在表达生殖系的FPD/MM HPC中,
mtRUNX1.提出的研究的具体目的是:目的1:为了确定对活性增强剂的影响,
BETP拮抗剂沿着其共抑制的转录组和临床前体外和体内功效
RUNX 1、BCL 2和CDK 6单独或与BCL 2或CDK 6抑制剂联合在AML原始细胞和患者中的作用
表达体细胞突变体RUNX 1的衍生异种移植(PDX)模型。此外,我们将评估临床前
共靶向CRISPR-Cas9筛选发现的与BETP一起沿着的顶级“可药物化”依赖性的功效
针对表达体细胞mtRUNX 1的AML母细胞的拮抗剂。目的2:阐明临床前体外和体内
EMs高三尖杉酯碱(omacetaxine)或非德拉替尼单独使用以及与BETP联合使用的体内疗效
针对患者来源的AML母细胞和表达体细胞mtRUNX 1的PDX模型的拮抗剂。目标3:
确定抑制RUNX 1及其靶点的选定EM的临床前体外和体内功效,
来自表达生殖系mtRUNX 1和其他体细胞共突变的FPD-MM的患者源性HPC与
来自RUNX 1-FPD的HPC仅表达种系mtRUNX 1。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KAPIL BHALLA其他文献
KAPIL BHALLA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KAPIL BHALLA', 18)}}的其他基金
Novel combination therapy for AML expressing mutant RUNX1
表达突变体 RUNX1 的 AML 的新型联合疗法
- 批准号:
10698087 - 财政年份:2021
- 资助金额:
$ 48.7万 - 项目类别:
Novel combination therapy for AML expressing mutant RUNX1
表达突变体 RUNX1 的 AML 的新型联合疗法
- 批准号:
10276033 - 财政年份:2021
- 资助金额:
$ 48.7万 - 项目类别:
Novel combination therapy for AML expressing mutant RUNX1
表达突变体 RUNX1 的 AML 的新型联合疗法
- 批准号:
10473712 - 财政年份:2021
- 资助金额:
$ 48.7万 - 项目类别:
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1
表达体细胞或种系突变体 RUNX1 的 AML 的生物学和新疗法
- 批准号:
10531564 - 财政年份:2020
- 资助金额:
$ 48.7万 - 项目类别:
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML
靶向转录组失调作为骨髓增殖后肿瘤 (MPN) sAML 的治疗方法
- 批准号:
10595080 - 财政年份:2020
- 资助金额:
$ 48.7万 - 项目类别:
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML
靶向转录组失调作为骨髓增殖后肿瘤 (MPN) sAML 的治疗方法
- 批准号:
10364667 - 财政年份:2020
- 资助金额:
$ 48.7万 - 项目类别:
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma
基于BET蛋白拮抗剂的套细胞淋巴瘤靶向治疗
- 批准号:
9888204 - 财政年份:2017
- 资助金额:
$ 48.7万 - 项目类别:
BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma
基于BET蛋白拮抗剂的套细胞淋巴瘤靶向治疗
- 批准号:
10132260 - 财政年份:2017
- 资助金额:
$ 48.7万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 48.7万 - 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 48.7万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 48.7万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 48.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 48.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 48.7万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 48.7万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 48.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 48.7万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 48.7万 - 项目类别:
Discovery Grants Program - Individual